FSD Pharma Announces Phase 2 Clinical Trial IND Filing with the FDA to Treat Patients with COVID-19
The study is expected to be conducted at 25-30 hospitals in North America – TORONTO, ON / ACCESSWIRE / August 31, 2020 / FSD Pharma Inc. (CSE:HUGE)(NASDAQ:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company”) today announced that it has submitted to the U.S. Food and Drug Administration (“FDA”) an Investigational New Drug Application (IND) for the use of FSD201 (ultramicronized palmitoylethanolamide, or […]